secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aldeyra Therapeutics, Inc. (ALDX)
CIK:        0001341235
Form:       8-K
Filed at:   2025-04-03T23:59:59+00:00
Accession:  0001193125-25-072424
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA issues Complete Response Letter for Aldeyra's reproxalap dry eye NDA; additional study required
--------------------------------------------------------------------------------

- FDA CRL states reproxalap 'failed to demonstrate efficacy' in adequate studies; no safety or manufacturing issues.
- Type A meeting expected within ~30 days; top-line data from ongoing chamber and field trials due Q2 2025.
- Aldeyra plans NDA resubmission mid-2025 pending positive results and FDA discussions; review period expected 6 months.
- Cash, equivalents, and marketable securities $101M as of Dec 31, 2024; 2025 trial costs ~$6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1341235/000119312525072424/0001193125-25-072424-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1341235/000119312525072424/d946200d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-072424

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer